Cramer: There will be push back on Biogen’s Alzheimer’s drug price

About This Source - CNBC Television

CNBC is an American pay television business news channel, which primarily carries business day coverage of U.S. and international financial markets. Following the end of the business day and on non-trading days, CNBC primarily carries financial and business-themed documentaries and reality shows.

As of February 2015, CNBC is available to approximately 93,623,000 pay television households (80.4% of households with television) in the United States.

Recent from CNBC Television:

  • Amazon union vote may get a ‘do-over’
  • Bodycam video from the night the Surfside condo collapsed
  • New report finds Lebanese government knew of the danger before explosion
  • CNBC Television published this video item, entitled “Cramer: There will be push back on Biogen’s Alzheimer’s drug price” – below is their description.

    The Food and Drug Administration on Monday approved Biogen’s Alzheimer’s disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer’s and the first new medicine for the disease in nearly two decades. CNBC’s Jim Cramer, Carl Quintanilla and David Faber discuss.

    CNBC Television YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    Leave a Comment